Top

International Journal of Colorectal Disease

Published in:

Open Access 01-03-2014 | Original Article

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study

Authors: Lukasz Krokowicz, Zoran Stojcev, Bartosz Filip Kaczmarek, Wojciech Kociemba, Elżbieta Kaczmarek, Jaroslaw Walkowiak, Piotr Krokowicz, Michal Drews, Tomasz Banasiewicz

Published in: International Journal of Colorectal Disease | Issue 3/2014

Abstract

Background

Microencapsulated sodium butyrate (MSB) has been previously associated with anti-inflammatory and regenerative properties regarding large bowel mucosa. We aimed to examine a role of MSB in patients with diverticulosis, hypothesizing its potential for reduction of diverticulitis episodes and diverticulitis prevention.

Methods

Seventy-three patients with diverticulosis (diagnosed in colonoscopy or/and barium enema or/and CT colography) were recruited for the study and randomized. The investigated group was administered MSB 300 mg daily; the control group was administered placebo. After 12 months, a total of 52 patients completed the study and were subject to analysis (30 subjects and 22 controls). During the study, the number of episodes of diverticulitis (symptomatic diagnosis with acute pain, fever, and leukocytosis), hospitalizations, and surgery performed for diverticulitis were recorded. Additionally, a question regarding subjective improvement of symptoms reflected changes in quality of life during the analysis.

Results

After 12 months, the study group noted a significantly decreased number of diverticulitis episodes in comparison to the control group. The subjective quality of life in the study group was higher than in the control group. There were no side effects of the MSB during the therapy.

Conclusions

MSB reduces the frequency of diverticulitis episodes, is safe, and improves the quality of life. It can play a role in the prevention of diverticulitis.

Parks TG (1975) Natural history of diverticular disease of the colon. Clin Gastroenterol 4:3–21

Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38:S2–S7PubMedCrossRef

Munson KD, Hensien MA, Jacob LN, Robinson AM, Liston WA (1996) Diverticulitis: a comprehensive follow-up. Dis Colon Rectum 39:318–324PubMedCrossRef

World Medical Association (2008) WMA Declaration of Helsinki—ethical principles for medical research involving human subjects, Seoul, Korea

Mizuki A, Nagata H, Tatemichi M, Kaneda S, Tsukada N, Ishii H, Hibi T (2005) The out-patient management of patients with acute mild-to-moderate colonic diverticulitis. Aliment Pharmacol Ther 21:889–897PubMedCrossRef

Ambrosetti P, Jenny A, Becker C, Terrier TF, Morel P (2000) Acute left colonic diverticulitis—compared performance of computed tomography and water-soluble contrast enema: prospective evaluation of 420 patients. Dis Colon Rectum 43(10):1363–1367PubMedCrossRef

Etzioni DA, Mack TM, Beart RW Jr, Kaiser AM (2009) Diverticulitis in the United States: 1998–2005: changing patterns of disease and treatment. Ann Surg 249:210–217PubMedCrossRef

Krukowski ZH, Matheson NA (1984) Emergency surgery for diverticular disease complicated by generalized and faecal peritonitis: a review. Br J Surg 71:921–927PubMedCrossRef

Wong WD, Wexner SD, Lowry A, Vernava A III, Burnstein M (2000) Practice parameters for the treatment of sigmoid diverticulitis—supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 43:290–297PubMedCrossRef

10.

Parks TG (1969) Natural history of diverticular disease of the colon. A review of 521 cases. Br Med J 4:639–642PubMedCentralPubMedCrossRef

11.

Peppas G, Bliziotis LA, Oikonomaki D, Falagas ME (2007) Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J Gastroenterol Hepatol 22:1360–1368PubMedCrossRef

12.

Brodribb AJ (1977) Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1:664–666PubMedCrossRef

13.

Ornstein MH, Littlewood ER, Baird IM, Fowler J, North WR, Cox AG (1981) Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed) 282:1353–1356CrossRef

14.

Lupton JR, Turner ND (1999) Potential protective mechanisms of wheat bran fiber. Am J Med 106:24–27CrossRef

15.

Tan KY, Seow-Choen F (2007) Fiber and colorectal diseases: separating fact from fiction. World J Gastroenterol 13:4161–4167PubMed

16.

Gronek P, Holdys J. (2013) Genes and physical fitness. Trends in Sport Sciences 20(1):16–29.

17.

Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–515PubMedCrossRef

18.

Colecchia A, Vestito A, Pasqui F, Mazzella G, Roda E, Pistoia F (2007) Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 13:264–269PubMed

19.

Fric P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef

20.

Giaccari S, Tronci S, Falconieri M, Ferrieri A (1993) Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Riv Eur Sci Med Farmacol 15:29–34PubMed

21.

Lamiki P, Tsuchiya J, Pathak S, Okura R, Solimene U, Jain S (2010) Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis 19:31–36PubMed

22.

Banasiewicz T, Krokowicz L, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M (2013) Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 15:204–209PubMedCrossRef

23.

Cordel S, Dupas B, Douillard JY, Meflah K (1998) Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. Int J Cancer 78:735–739PubMedCrossRef

24.

Hall JF, Roberts PL, Ricciardi R (2011) Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum 54:283–288PubMedCrossRef

25.

Vernia P, Annese V, Bresci G, d'Albasio G, D'Incà R, Giaccari S (2003) Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Investig 33:244–248CrossRef

26.

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27:104–119PubMedCrossRef

27.

Topping DL, Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81:1031–1064PubMed

28.

Canani RB, Terrin G, Cirillo P, Castaldo G, Salvatore F, Cardillo G, Coruzzo A, Troncone R (2004) Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 127:630–634PubMedCrossRef

29.

Schmitt MG Jr, Soergel KH, Wood CM (1976) Absorption of short chain fatty acids from the human jejunum. Gastroenterology 70:211–215PubMed

30.

Clemens CH, Samsom M, Roelofs J, van Berge Henegouwen GP, Smout AJ (2004) Colorectal visceral perception in diverticular disease. Gut 53:717–722PubMedCentralPubMedCrossRef

31.

Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamanga G (2006) Review article: uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther 23:1379–1391PubMedCrossRef

32.

Roda A, Simoni P, Magliulo M, Nanni P, Baraldini M, Roda G, Roda E (2007) A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. World J Gastroenterol 13:1079–1084PubMed

33.

Zullo A, Hassan C, Maconi G, Manes G, Tammaro G, De Francesco V, Annibale B, Ficano L, Buri L, Gatto G, Lorenzetti R, Campo SM, Ierardi E, Pace F, Morini S (2010) Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. J Gastrointestin Liver Dis 19:295–302PubMed

34.

Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW (2003) Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 98:122–127PubMedCrossRef

35.

IIrvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ et al (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130:1538–1551CrossRef

Title: Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study
Authors: Lukasz Krokowicz
Zoran Stojcev
Bartosz Filip Kaczmarek
Wojciech Kociemba
Elżbieta Kaczmarek
Jaroslaw Walkowiak
Piotr Krokowicz
Michal Drews
Tomasz Banasiewicz
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 3/2014
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-013-1807-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Tamponade dressings may be unnecessary after haemorrhoidectomy: a randomised controlled clinical trial

Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer

Giant cell tumor of the distal common bile duct: report of a rare, benign entity that may mimic malignant biliary obstruction

A virtual outpatient department provides a satisfactory patient experience following endoscopy

The impact of visceral obesity on surgical outcomes of laparoscopic surgery for colon cancer

A prospective randomized controlled trial of subcutaneous passive drainage for the prevention of superficial surgical site infections in open and laparoscopic colorectal surgery